SCHEMBL570067

SCHEMBL570067

CCn1nc(-c2ccc(O)cc2)c2ncccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 7/20 0.42
NAMPT P43490 3/20 0.40
KDM4E B2RXH2 4/20 0.40
KMT2A Q03164 3/20 0.40
USP2 O75604 2/20 0.40
MAPK1 P28482 2/20 0.40
MEN1 O00255 1/20 0.40
TNNI3 P19429 1/20 0.40
CRHBP P24387 1/20 0.40
CASP1 P29466 1/20 0.40
TNNT2 P45379 1/20 0.40
CASP7 P55210 1/20 0.40
TNNC1 P63316 1/20 0.40
ATM Q13315 1/20 0.40
CRHR2 Q13324 1/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
TLR9 Q9NR96 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL570261 0.93 MEN1 (0.44) NAMPTKDM4EKMT2AUSP2MAPK1
SCHEMBL571142 0.85 TBXAS1 (0.37) ESR1NAMPTKDM4EKMT2AUSP2
SCHEMBL15065058 0.83 MEN1 (0.40) NAMPTKDM4EKMT2AUSP2MAPK1
SCHEMBL15064788 0.82 RORC (0.37) ESR1NAMPTKDM4EL3MBTL1
SCHEMBL569941 0.82 ESR1 (0.39) ESR1KDM4EL3MBTL1PDE1APDE1B
SCHEMBL15064423 0.81 NAMPT (0.53) ESR1NAMPTKDM4EKMT2AMAPK1
SCHEMBL570610 0.79 MAPK1 (0.44) ESR1KDM4EKMT2AUSP2MAPK1
SCHEMBL570750 0.78 PTGS2 (0.40) NAMPTKDM4EKMT2AUSP2MAPK1
SCHEMBL15064667 0.78 FYN (0.37) PDE1APDE1BPDE1C
SCHEMBL18561572 0.77 KDR (0.47) ESR1NAMPTKDM4EKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601192-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICALS CO (JP) 2017-03-01 EP disclosed
US-9029536-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-12 US disclosed
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-04 US disclosed
EP-2601192-A1 FUSED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2013-06-12 EP disclosed
WO-2012018909-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS PDE10A, PDE3A, PDE2A ESR1 1158/4885NAMPT 2363/4885KDM4E 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.